Please assess the completion status of the following clinical trial:

Trial Title: Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with poor or no response in previous COH for IVF cycles~* Patients with AMH \< 1 and/or FSH \>12~* Poor quality of embryos in previous cycles~* Age of patients up to 44 years~Exclusion Criteria:~* Patients with normal ovarian reserve~* Patients with sonographically detected hydrosalpinges~* Presence of intramural fibroid distorting the endometrial cavity or submucous myoma or Asherman's syndrome~* Women with thrombofilia disorders

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Oestradiol and ultrashort GnRH agonist/antagonist protocol (Type: EXPERIMENTAL): Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
- GnRH agonist or antagonist protocol. (Type: ACTIVE_COMPARATOR): Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF

Based on this trial design, predict the completion outcome and termination type (if applicable).